Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy

Tong WH, van der Sluis IM, Alleman CJM, van Litsenburg RRL, Kaspers GJL, Pieters R, Uyl-De Groot CA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23403311

DOI
10.3324/haematol.2012.073510

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Antineoplastic Agents /adverse effects /economics /therapeutic use; Asparaginase /adverse effects /economics /therapeutic use; Child; Child, Preschool; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Female; Health Care Costs; Humans; Infant; Male; Models, Economic; Precursor Cell Lymphoblastic Leukemia-Lymphoma /drug therapy /economics

AccessionNumber
22013021884

Date bibliographic record published
25/06/2013